Furthermore, patients were stratified based on clinical groups: ERα-positive/HER2-negative (n = 2308), ERα-positive/HER2-positive (n = 287), ERα-negative/HER2-positive (n = 124) and triple-negative breast cancer (TNBC, n = 320). The gene discussed is ERBB2; the disease is triple-negative breast carcinoma.